

# A randomised controlled trial of rectal versus oral acetaminophen antipyresis in children

<b>Submission date</b> 04/03/2005	<b>Recruitment status</b> No longer recruiting	<input type="checkbox"/> Prospectively registered <input type="checkbox"/> Protocol
<b>Registration date</b> 10/03/2005	<b>Overall study status</b> Completed	<input type="checkbox"/> Statistical analysis plan <input checked="" type="checkbox"/> Results
<b>Last Edited</b> 20/12/2007	<b>Condition category</b> Signs and Symptoms	<input type="checkbox"/> Individual participant data

**Plain English summary of protocol**  
Not provided at time of registration

## Contact information

**Type(s)**  
Scientific

**Contact name**  
Dr Mona Nabulsi

**Contact details**  
American University of Beirut Medical Center  
Beirut  
Lebanon  
113-6044/C8  
+961 (0)3 628528  
mn04@aub.edu.lb

## Additional identifiers

EudraCT/CTIS number

IRAS number

ClinicalTrials.gov number

**Secondary identifying numbers**  
N/A

## Study information

## Scientific Title

### Study objectives

This randomised, double-dummy and placebo controlled study was conducted to compare the antipyretic efficacies of two different rectal doses of acetaminophen: 15 mg/kg and 35 mg/kg to that of a standard oral dose of 15 mg/kg, over a six-hour period, to allow detection of late antipyresis that may occur with rectal acetaminophen. The results of this study will provide further evidence on the comparative antipyretic efficacy of different doses of rectal acetaminophen versus the standard oral one.

Our study hypothesis was that a single dose of 15 mg/kg oral acetaminophen is more effective than either 15 mg/kg or 35 mg/kg rectal acetaminophen, in reducing the temperature of febrile children.

### Ethics approval required

Old ethics approval format

### Ethics approval(s)

The Institutional Review Board and the Ethics Committee at the American University of Beirut, as well as the Board of the Middle East Hospital, approved this study.

### Study design

Randomised controlled trial

### Primary study design

Interventional

### Secondary study design

Randomised controlled trial

### Study setting(s)

Hospital

### Study type(s)

Treatment

### Participant information sheet

### Health condition(s) or problem(s) studied

Fever

### Interventions

Group 1: A single dose of oral acetaminophen (15 mg/kg) plus placebo rectal suppository (size equivalent to a 35 mg/kg rectal acetaminophen suppository)

Group 2: A single dose of oral placebo (equivalent to a 15 mg/kg oral acetaminophen) plus a rectal suppository containing 15 mg/kg acetaminophen and 20 mg/kg placebo.

Group 3: A single dose of oral placebo as in group 2 plus a rectal suppository of 35 mg/kg acetaminophen.

Rectal temperature readings at baseline and hourly for a total of 6 hours.

**Intervention Type**

Drug

**Phase**

Not Specified

**Drug/device/biological/vaccine name(s)**

Acetaminophen

**Primary outcome measure**

Time to maximum antipyresis following administration of a single dose of acetaminophen.

**Secondary outcome measures**

Secondary outcomes included the temperatures at one, two, three, four, five, and six hours from administration and possible side effects such as hypothermia.

**Overall study start date**

01/11/2000

**Completion date**

30/09/2002

**Eligibility****Key inclusion criteria**

1. Age between 6 months and 13 years
2. Rectal temperature greater than or equal to 38.5 °C
3. Consent of treating physician
4. Written consent of parent and oral consent of child if older than 10 years
5. No antipyretic intake for 8 hours prior to enrolment

**Participant type(s)**

Patient

**Age group**

Child

**Lower age limit**

6 Months

**Upper age limit**

13 Years

**Sex**

Both

**Target number of participants**

48

**Key exclusion criteria**

1. Presence of concurrent or previous hepatic disease
2. Chronic and/or serious disease such as malignancy, septic shock, malabsorption syndromes etc.
3. Any condition interfering with the absorption of oral or rectal acetaminophen such as vomiting or severe diarrhoea, ileus, rectal bleeding etc.
4. Hypersensitivity to acetaminophen

**Date of first enrolment**

01/11/2000

**Date of final enrolment**

30/09/2002

**Locations****Countries of recruitment**

Lebanon

**Study participating centre**

American University of Beirut Medical Center

Beirut

Lebanon

113-6044/C8

**Sponsor information****Organisation**

American University of Beirut (Lebanon)

**Sponsor details**

Faculty of Medicine, Medical Practice Plan

Riyad El-Solh

Beirut

Lebanon

11-02-36

+961 (0)1 350000

resdean@aub.edu.lb

**Sponsor type**

University/education

**Website**

<http://www.aub.edu.lb/>

ROR

## Funder(s)

### Funder type

University/education

### Funder Name

American University of Beirut (Lebanon) - Medical Practice Plan of the Faculty of Medicine (grant ref: AUB A/C 686056)

## Results and Publications

### Publication and dissemination plan

Not provided at time of registration

### Intention to publish date

### Individual participant data (IPD) sharing plan

### IPD sharing plan summary

Not provided at time of registration

### Study outputs

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
<a href="#">Results article</a>	Results	06/09/2005		Yes	No